<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526588</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0148</org_study_id>
    <nct_id>NCT03526588</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)</brief_title>
  <official_title>Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Medical Center Regenerative Medicine Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB)
      mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk
      congenital diaphragmatic hernia (CDH).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by vital sign monitoring (heart rate)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign monitoring (systolic blood pressure)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign monitoring (diastolic blood pressure)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign monitoring (temperature)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by pulmonary status (indicated by peak inspiratory pressure (PIP))</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by pulmonary status (indicated by positive end expiratory pressure (PEEP))</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by pulmonary status (indicated by respiratory rate (RR))</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by pulmonary status (indicated by Fraction of inspired oxygen (FiO2))</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by presence of new infiltrates or altered aeration upon chest radiography</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by cardiovascular status (indicated by heart rate)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by cardiovascular status (indicated by systolic blood pressure)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by cardiovascular status (indicated by diastolic blood pressure)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by cardiovascular status (indicated by changes in cardiovascular pharmacologic support)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by infection status (indicated by body temperature)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by infection status (indicated by white blood cell count)</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by infection status (indicated by physical signs of infection)</measure>
    <time_frame>daily for 7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by liver function (indicated by Alanine aminotransferase (ALT) levels)</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by liver function (indicated by aspartate aminotransferase (AST) levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by liver function (indicated by bilirubin levels)</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by liver function (indicated by albumin levels)</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by blood urea nitrogen (BUN) levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by creatinine levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by carbon dioxide (CO2) levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by glucose levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by serum chloride levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by serum potassium levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by serum sodium levels</measure>
    <time_frame>7 days following the initial infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurologic/neurodevelopmental status as assessed by intracranial abnormalities upon magnetic resonance imaging (MRI)</measure>
    <time_frame>within 14 days of discharge (discharge occurs at about 2-4 months after birth)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurologic/neurodevelopmental status as assessed by receipt of neurologic pharmacologic medications</measure>
    <time_frame>at the time of discharge (which is about 2-4 months after birth)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurologic/neurodevelopmental status as assessed by Bayley Scales of Infant and Toddler Development-III (BSID-III)</measure>
    <time_frame>2 years after birth</time_frame>
    <description>The Bayley-III is an individually-administered examination that assesses the current developmental functioning of infants and young children from birth to 42 months of age. The Bayley is a standardized, norm-referenced measure that assesses development in Cognitive, Language and Motor domains. Composite standard scores can be derived that have a mean of 100 and a standard deviation of 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>from birth to discharge or death, whichever occurs first (discharge occurs at about 2-4 months after birth)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of pulmonary hypertension as assessed by echocardiography</measure>
    <time_frame>within 24 hours of birth, prior to operative repair (occurs between day 2 &amp; 14 of life), prior to discharge (usually 2-6 months), and after discharge (2wks-6 months following discharge)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of extracorporeal membrane oxygenation (ECMO) support</measure>
    <time_frame>days from ECMO initiation until decannulation (an average of 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilatory support</measure>
    <time_frame>from initiation of ventilation until extubation (an average of 8 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congenital Diaphragmatic Hernia</condition>
  <arm_group>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous umbilical cord blood</intervention_name>
    <description>6Ã—10^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.</description>
    <arm_group_label>Autologous umbilical cord blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CDH between 20 and 36 weeks estimated gestational age (EGA)

          -  Only one of the following fetal criteria and one of the following postnatal criteria
             must be met for enrollment. Fetal criteria: an ultrasound (US)-obtained observed to
             expected lung to head ratio (o/e LHR) less than or equal to 35% or 2) a fetal magnetic
             resonance imaging (fMRI)- obtained observed to expected total fetal lung volume (o/e
             TFLV) less than or equal to 35%. Postnatal criteria: 1) Cord blood gas (CBG) with
             potenital hydrogen (pH) &lt;7.0, 2) Arterial blood gas (ABG) with pH &lt;7.2 on 2 gasses
             within the first 24 hours, 3) Preductal oxygen saturation (O2 sat) &lt;90% x 2 total
             hours (not necessarily consecutive) within the first 24 hours, or 4) Oxygenation Index
             (OI) &gt;20 x 2 total hours (not necessarily consecutive) within the first 24 hours.

        Exclusion Criteria:

          -  Genetic/chromosomal abnormality: Trisomy 21, Trisomy 18, Trisomy 13 or other,
             significant genetic abnormality. Microdeletions or other mild genetic abnormalities
             are not considered exclusionary.

          -  Severe/major cardiac anomaly: coarctation of the aorta, combined atrial and
             ventricular septal defects, hypoplastic left heart syndrome, tetralogy of fallot,
             double outlet right ventricle, atrioventricular canal defects, or other
             hemodynamically significant defects.

          -  Moderate/severe neurologic / intracranial abnormality: Grade III or IV
             intraparenchymal hemorrhage, space occupying mass or lesion, or clinically significant
             traumatic lesion such as a subdural or epidural hemorrhage.

          -  Prematurity &lt;30 weeks estimated gestational age (EGA): Birth at 29 6/7 weeks or before

          -  Participation in an alternative prenatal intervention study: Fetoscopic Endotracheal
             Occlusion (FETO)

          -  Unwillingness / inability to return for follow-up evaluation and assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew T. Harting, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew T. Harting, MD, MS</last_name>
    <phone>713-500-7300</phone>
    <email>Matthew.T.Harting@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew T. Harting, MD, MS</last_name>
      <phone>832-325-7234</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Matthew Tihen Harting</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>CDH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Diaphragmatic</mesh_term>
    <mesh_term>Hernias, Diaphragmatic, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

